Clinical Trials in Follow-Up
4FRONT-1
Pathology: Treatment Naïve nAMD
Description: A phase 3, randomized, double-masked, active-controlled trial of a singular intravitreal injection of 4D-150 in adults with macular neovascularization secondary to age-related macular degeneration
4FRONT-2
Pathology: Treatment Naïve and experienced nAMD
Description: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
ARTEMIS
Pathology: Treatment Naïve nAMD
Description: A multi-center, randomized, double-masked, active-comparator-controlled, phase 3 study to evaluate the efficacy and safety of Ixoberogene Soroparvovec (Ixo-vec) in participants with neovascular age-related macular degeneration
ATMOSPHERE
Pathology: Pseudophakic with nAMD
Description: A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
ATMOSPHERE EXTENSION
Pathology: nAMD
Description: A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy
BURGUNDY
Pathology: nAMD
Description: A phase 1/2a study evaluating the study evaluating the safety, tolerability, and efficacy of zifbancimig for treating neovascular age-related macular degeneration (nAMD)
DAYBREAK
Pathology: Treatment Naïve nAMD
Description: A prospective, randomized, double-masked, active comparator-controlled, multicenter, three-arm phase 3 study to evaluate the efficacy and safety of intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer compared with intravitreal Aflibercept in participants with neovascular (Wet) age-related macular degeneration (wAMD)
DRCR AO
Pathology: Neovascular AMD
Description: A home OCT-guided treatment versus treat and extend for the management of neovascular AMD
EDIC
Pathology: Diabetic Retina Diseases
Description: Epidemiology of Diabetes Interventions and Complications currently in year 30 of the trial
JANSSEN GENE THERAPY TRIAL & EXTENSION
Pathology: Geographic Atrophy (GA)
Description: A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD).
Extension Description: Long-term extension study of participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in JNJ-81201887 parent clinical studies. Protocol 81201887MDG3002; Phase 2b
JOURNEY
Pathology: Geographic Atrophy
Description: Phase 1/2a Study of VOY-101 in Subjects with Advanced Non-Neovascular Age-Related Macular Degeneration
LUGANO
Pathology: nAMD
Description: A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
NIRVANA
Pathology: Geographic Atrophy
Description: Non-Interventional Observational Natural History Study of Early Geographic Atrophy Due to CFH-Risk Age-Related Macular Degeneration
OCU410ST -GUARDIAN
Pathology: Stargardt’s Disease
Description: A phase 1 study to assess the safety and efficacy of OCU410ST for Stargardt Disease and phase 2/3 pivotal confirmatory clinical trial to assess the safety and efficacy of OCU410ST for Stargardt Disease
PREGONDA
Pathology: Diabetic Macular Edema
Description: A phase I, multipart, multicenter study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7497372 following intravitreal administration in participants with diabetic macular edema (Part 1 non-randomized, open-label, multiple ascending doses, Part 2 randomized, double-masked)
SOL-1 & SOL-R
Pathology: Wet AMD
Description: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
VILLA
Pathology: nAMD
Description: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema